Evaluating the cytotoxicity of flaxseed orbitides for potential cancer treatment

Toxicology Reports

Volumn 2, Issue , 2015, Pages 1014-1018

  Okinyo Owiti, Denis P ^a   Dong, Qiulin ^a   Ling, Binbing ^a   Jadhav, Pramodkumar D ^a   Bauer, Robert ^a   Maley, Jason M ^b   Reaney, Martin J T ^a   Yang, Jian ^a   Sammynaiken, Ramaswami ^b  

^a UNIVERSITY OF SASKATCHEWAN   (Canada)

^b UNIVERSITY OF SASKATCHEWAN   (Canada)

Author keywords

Breast cancer; Cytotoxicity; Flaxseed linoorbitide; Melanoma

Indexed keywords

LINOORBITIDE; PHOSPHOLIPID; PLANT MEDICINAL PRODUCT; TRASTUZUMAB; UNCLASSIFIED DRUG;

ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ARTICLE; BREAST CANCER; CANCER THERAPY; CELL PROTECTION; CONTROLLED STUDY; CYTOTOXICITY; HUMAN; HUMAN CELL; HYDROPHOBICITY; LINSEED; MELANOMA; PROTEIN INTERACTION; REVERSED PHASE HIGH PERFORMANCE LIQUID CHROMATOGRAPHY;

EID: 84937834232     PISSN: 22147500     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.toxrep.2015.06.011     Document Type: Article

References (24)

1. Bommareddy A., Zhang X.Y., Kaushik R.S., Dwivedi C. Effects of components present in flaxseed on human colon adenocarcinoma Caco-2 cells: possible mechanisms of flaxseed on colon cancer development in animals. Drug Discov. Ther. 2010, 4:184-189.
2. Gui B., Shim Y.Y., Datla R.S., Covello P.S., Stone S.L., Reaney M.J. Identification and quantification of cyclolinopeptides in five flaxseed cultivars. J. Agric. Food Chem. 2012, 60:8571-8579.
3. Mabrok H.B., Klopfleisch R., Ghanem K.Z., Clavel T., Blaut M., Loh G. Lignan transformation by gut bacteria lowers tumor burden in a gnotobiotic rat model of breast cancer. Carcinogenesis 2012, 33:203-208.
4. Okinyo-Owiti D.P., Young L., Burnett P.G., Reaney M.J. New flaxseed orbitides: detection, sequencing, and 15N incorporation. Biopolymers 2014, 102:168-175.
5. Hu C.Q., Xu J.C. Amino acids and peptides. Introduction to Natural Products Chemistry 2012, 147-167. CRC Press, Boca Roton. R. Xu, Y. Ye, W. Zhao (Eds.).
6. Górski A., Kasprzycka M., Nowaczyk M., Wieczoreck Z., Siemion I.Z., Szelejewski W., Kutner A. Cyclolinopeptide: a novel immunosuppressive agent with potential anti-lipemic activity. Transplant. Proc. 2001, 33:553.
7. Drygała P., Olejnik J., Mazur A., Kierus K., Jankowski S., Zimecki M., Zabrocki J. Synthesis and immunosuppressive activity of cyclolinopeptide A analogues containing homophenylalanine. Eur. J. Med. Chem. 2009, 44:3731-3738.
8. Thevenard J., Ramont L., Devy J., Brassart B., Dupont-Deshorgue A., Floquet N., Schneider L., Ouchani F., Terryn C., Maquart F.X., Monboisse J.C., Brassart-Pasco S. The YSNSG cyclopeptide derived from tumstatin inhibits tumor angiogenesis by down-regulating endothelial cell migration. Int. J. Cancer 2010, 126:1055-1066.
9. Yu R., Wang J., Li J., Wang Y., Zhang H., Chen J., Huang L., Liu X. A novel cyclopeptide from the cyclization of PACAP(1-5) with potent activity towards PAC1 attenuates STZ-induced diabetes. Peptides 2010, 31:1062-1067.
10. Chang M., Li X., Sun Y., Cheng F., Li Y., Zhao W., Wang Q. A potential mechanism of a cationic cyclopeptide for enhancing insulin delivery across Caco-2 cell monolayers. Biol. Pharm. Bull. 2013, 36:1602-1607.
11. Fang X.Y., Chen W., Fan J.T., Song R., Wang L., Gu Y.H., Zeng G.Z., Shen Y., Wu X.F., Tan N.H., Xu Q., Sun Y. Plant cyclopeptide RA-V kills human breast cancer cells by inducing mitochondria-mediated apoptosis through blocking PDK1-AKT interaction. Toxicol. Appl. Pharmacol. 2013, 267:95-103.
12. Goyal A., Sharma V., Upadhyay N., Gill S., Sihag M. Flax and flaxseed oil: an ancient medicine & modern functional food. J. Food Sci. Technol. 2014, 51:1633-1653.
13. Boivin V., Beyersdorf N., Palm D., Nikolaev V.O., Schlipp A., Müller J., Schmidt D., Kocoski V., Kerkau T., Hünig T., Ertl G., Lohse M.J., Jahns R. Novel receptor-derived cyclopeptides to treat heart failure caused by anti-β1-adrenoceptor antibodies in a human-analogous rat model. PLOS ONE 2015, 10:e0117589.
14. Li P., Jiang S., Lee S.L., Lin C.Y., Johnson M.D., Dickson R.B., Michejda C.J., Roller P.P. Design and synthesis of novel and potent inhibitors of the type II transmembrane serine protease, matriptase, based upon the sunflower trypsin inhibitor-1. J. Med. Chem. 2007, 50:5976-5983.
15. Quimbar P., Malik U., Sommerhoff C.P., Kaas Q., Chan L.Y., Huang Y.H., Grundhuber M., Dunse K., Craik D.J., Anderson M.A., Daly N.L. High-affinity cyclic peptide matriptase inhibitors. J. Biol. Chem. 2013, 288:13885-13896.
16. Barnes P.M., Bloom B., Nahin R. Complementary and Alternative Medicine Use Among Adults and Children: United States, 2007, CDC National Health Statistics Report #12 2008.
17. Chen J., Stavro P.M., Thompson L.U. Dietary flaxseed inhibits human breast cancer growth and metastasis and downregulates expression of insulin-like growth factor and epidermal growth factor receptor. Nutr. Cancer 2002, 43:187-192.
18. Eilati E., Bahr J.M., Hales D.B. Long term consumption of flaxseed enriched diet decreased ovarian cancer incidence and prostaglandin E2 in hens. Gynecol. Oncol. 2013, 130:620-628.
19. Mason J.K., Thompson L.U. Flaxseed and its lignan and oil components: can they play a role in reducing the risk of and improving the treatment of breast cancer?. Appl. Physiol. Nutr. Metab. 2014, 39:663-678.
20. Mason J.K., Fu M., Chen J., Thompson L.U. Flaxseed oil enhances the effectiveness of trastuzumab in reducing the growth of HER2-overexpressing human breast tumors (BT-474). J. Nutr. Biochem. 2015, 26:16-23.
21. Sharav O., Shim Y.Y., Okinyo-Owiti D.P., Sammynaiken R., Reaney M.J. Effect of cyclolinopeptides on the oxidative stability of flaxseed oil. J. Agric. Food Chem. 2014, 62:88-96.
22. Lipinski C.A., Lombardo F., Dominy B.W., Feeney P.J. Experimental and computational approaches to estimate solubility and permeability in drug discovery and development settings. Adv. Drug Deliv. Rev. 2001, 46:3-26.
23. Gellman S.H. On the role of methionine residues in the sequence independent recognition of nonpolar protein surfaces. Biochemistry 1991, 30:6633-6636.
24. Siemion I.Z., Cebrat M., Wieczorek Z. Cyclolinopeptides and their analogs - a new family of peptide immunosuppressants affecting the calcineurin system. Arch. Immunol. Ther. Exp. (Warsz) 1999, 47:143-153.